肝脏 ›› 2022, Vol. 27 ›› Issue (3): 325-329.

• 肝功能衰竭 • 上一篇    下一篇

HBV-ACLF患者DPMAS序贯血浆置换治疗前后血清PA/TB、AFP水平变化与疗效及预后的评估价值

皇甫彤, 蔺咏梅, 陆长春, 何莹, 饶珂萌   

  1. 723000 陕西汉中 西安交通大学附属三二〇一医院
  • 收稿日期:2021-05-07 出版日期:2022-03-31 发布日期:2022-05-31
  • 基金资助:
    陕西省社会发展科技攻关项目(2016SF10625)

Correlation between the ratio of PA/TB, serum level of AFP and the efficacy and prognosis of sequential plasma exchange with DPMAS in HBV-ACLF patients

HUANG Fu-tong, LIN Yong-mei, LU Chang-chun, HE Ying, RAO Ke-meng   

  1. 3201 Hospital Affiliated to Xi'an Jiaotong University, Hanzhong 723000, China
  • Received:2021-05-07 Online:2022-03-31 Published:2022-05-31

摘要: 目的 探讨前白蛋白与总胆红素比值(PA/TB)、甲胎蛋白(AFP)与乙型肝炎相关慢加急性肝衰竭(HBV-ACLF)患者双重血浆分子吸附系统(DPMAS)序贯血浆置换治疗疗效和预后的相关性。方法 选择60例行DPMAS序贯血浆置换治疗的HBV-ACLF患者,治疗前后均采集静脉血检测血清前白蛋白(PA)、总胆红素(TBil)、AFP,计算PA/TB比值。治疗后随访90 d,分析影响HBV-ACLF患者90 d内死亡的因素以及PA/TB比值、AFP预测HBV-ACLF患者90 d内死亡的价值。结果 60例患者均完成DPMAS序贯血浆置换治疗,25例好转,35例未好转,随访期间死亡39例,存活21例。治疗后血清TBIL水平降低(P<0.05),PA、PA/TB比值、AFP增高(P<0.05)。好转组治疗后血清PA、AFP水平、PA/TB比值分别为(215.21±4.02)g/L、(220.12±7.95)ng/mL、(38.05±1.54)高于未好转组的(204.92±5.06)g/L、(179.20±10.05)ng/mL、(33.34±2.05)(P<0.05),血清TBil水平为(4.51±0.36)mg/dL,低于未好转组的(7.42±0.77)mg/dL(P<0.05)。死亡组血清TBil水平为(7.15±0.69)mg/dL,高于存活组的(4.46±0.30)mg/dL(P<0.05),AFP、PA、PA/TB比值分别为(206.03±6.12)g/L、(183.83±15.21)ng/mL、(32.94±1.39)低于存活组的(215.12±3.26)g/L、(219.32±8.52)ng/mL、(39.68±0.30)(P<0.05)。合并肝性脑病、低AFP、低PA/TB比值是导致HBV-ACLF患者90 d内死亡的危险因素(P<0.05)。联合PA/TB比值和AFP预测HBV-ACLF患者90 d内死亡的曲线下面积(AUC)为0.920,高于单独PA/TB比值、AFP的0.688、0.685(P<0.05)。结论 PA/TB比值和AFP降低与HBV-ACLF患者DPMAS序贯血浆置换治疗后疗效欠佳以及预后不良均有关,可作为HBV-ACLF患者预后判断的标志物。

关键词: 前白蛋白, 总胆红素, 甲胎蛋白, 乙型肝炎, 肝衰竭, 血浆置换

Abstract: Objective To investigate the correlation between the ratio of pre-albumin to total bilirubin (PA/TB) and serum level of alpha-fetoprotein (AFP) and the efficacy and prognosis of sequential plasma exchange with dual plasma molecular adsorption system (DPMAS) in patients with hepatitis B related acute on chronic live failure (HBV-ACLF).Methods Sixty HBV-ACLF patients who underwent sequential plasma exchange with DPMAS were selected. Before and after the treatment, venous blood was collected to detect serum pre-albumin (PA), total bilirubin (TBil) and AFP, and PA/TB ratio was calculated. After 90 days of follow-up post treatment, the factors affecting the death of HBV-ACLF patients within 90 days and the value of PA/TB ratio and AFP in predicting death within 90 days of HBV-ACLF patients were analyzed.Results Within all the 60 patients that had accomplished the treatment of sequential plasma exchange with DPMAS, 25 cases improved, 35 cases did not improve, 39 cases died and 21 cases survived during the follow-up. After the treatment, serum TBIL level decreased (P<0.05), while PA, PA/TB ratio and AFP increased (P<0.05). The serum levels of PA, AFP and PA/TB in the improved group were (215.21±4.02)g/L,(220.12±7.95)ng/mL, and(38.05±1.54)respectively,which were higher than (204.92±5.06)g/L, (179.20±10.05) ng/mL, and (33.34±2.05) respectively, in the non-improved group (P<0.05). The serum TBil level was(4.51±0.36)mg/dl in the improved group, which was lower than(7.42±0.77)mg/dL in the non-improved group (P<0.05). Serum TBIL level in the death group was(7.15±0.69)mg/dL which was higher than(4.46±0.30)mg/dL in the survival group (P<0.05). Serum AFP and PA levels, ratio of PA/TB in the death group were (206.03±6.12)g/L,(183.83±15.21)ng/mL, and(32.94±1.39) respectively, which were lower than(215.12±3.26)g/L,(219.32±8.52)ng/mL, and(39.68±0.30)respectively, in the survival group (P<0.05). Hepatic encephalopathy, low AFP and low PA/TB ratio were the risk factors for death in HBV-ACLF patients within 90 days (P<0.05). The area under the curve (AUC) of the combined PA/TB ratio and AFP in predicting HBV-ACLF death within 90 days was 0.920, which was higher than that of PA/TB ratio (AUC=0.688) and AFP (AUC=0.685) alone (P<0.05).Conclusion Decreased PA/TB ratio and serum level of AFP are associated with poor efficacy and poor prognosis after sequential plasma exchange with DPMAs in HBV-ACLF patients, which can be used as prognostic evaluating markers of HBV-ACLF patients.

Key words: Pre-albumin, Total bilirubin, Alpha fetoprotein, Hepatitis B, acute on chronic live failure, Plasma exchange, dual plasma molecular adsorption system